Table 2.
Baseline characteristics in the subgroups of patients with low and high PD-L1 TPS.
| Variable | PD-L1 < 50% (n = 40) | PD-L1 ≥ 50% (n = 12) | p Value |
|---|---|---|---|
| Age | |||
| <65 year | 31 (77.5%) | 10 (83.3%) | 1.000 |
| ≥65 year | 9 (22.5%) | 2 (16.7%) | |
| Sex | |||
| Male | 16 (40.0%) | 5 (41.7%) | 1.000 |
| Female | 24 (60.0%) | 7 (58.3%) | |
| Smoking status | |||
| Never | 28 (70.0%) | 10 (83.3%) | 0.475 |
| Former/current | 12 (30.0%) | 2 (16.7%) | |
| Stage | |||
| IIIB–IIIC | 3 (7.5%) | 0 | 1.000 |
| IV | 37 (92.5%) | 12 (100.0%) | |
| ECOG PS | 0.103 | ||
| 0 | 15 (37.5%) | 3 (25.0%) | |
| 1 | 22 (55.0%) | 5 (41.7%) | |
| 2 | 3 (7.5%) | 4 (33.3%) | |
| Metastasis | |||
| Brain | 12 (30.0%) | 6 (50.0%) | 0.300 |
| Bone | 17 (42.5%) | 7 (58.3%) | 0.510 |
| Liver | 8 (20.0%) | 3 (25.0%) | 0.701 |
| Adrenal glands | 3 (7.5%) | 1 (8.3%) | 1.000 |
| Pleura | 10 (25.0%) | 3 (25.0%) | 1.000 |
| Contralateral lung | 11 (27.5%) | 7 (58.3%) | 0.082 |
| TKI | |||
| Crizotinib | 32 (80.0%) | 10 (83.3%) | 1.000 |
| Alectinib | 8 (20.0%) | 2 (16.7%) |
ECOG PS, Eastern Cooperative Oncology Group performance status; PD-L1, programmed cell death-ligand 1; TKI, tyrosine kinase inhibitor.